md-medicaldata

Authors

 

Milan Tešić¹, Biserka Vukomanović Đurđević², Miroslav Broćić¹, Srboljub Stošić¹, Milka Gardašević¹, Saša Jović¹, Marko Brkić<sup>1

1</sup>Military Medical Academy, Clinic for Maxillofacial surgerybr /> ²Military Medical Academy, Institute for Pathology and Forensic medicine

 

UDK: 616.5-006.6

The paper was received / Rad primljen: 02.11.2021.

Accepted / Rad prihvaćen: 07.12.2021.

 

Correspondence to:

Dr Milan Tešić
Military Medical Academy
Crnotravska Street no. 17, 11040 Belgrade, Serbia
+381 11 3608 459
e-mail: dr.milantesic@gmail.com

 

 

Sažetak

 

Uvod: Bazocelularni karcinom (BCC) kože je najčešći tip karcinoma kože sa konstantnim porastom globalne incidence obolevanja. Predstavlja oko 80% svih nemelanomskih karcinoma kože, a vodi poreklo od bazalnih ćelija epidermisa. Karakteriše se lokalno destruktivnim rastom što može imati posledice na funkcionalne i estetske ishode, a pojava metastaza je retka. Trenutno dostupne metode lečenja su hirurške i nehirurške. Prikaz slučaja: Izveštavamo o našem iskustvu sa pacijentom kojem je u dobi od 45. godina učinjena ekscizija primarnog BCC kože nazoorbitalne regije i koji je potom razvio lokalno uznapredovali BCC i metastatski BCC, sa evolucijom od 9 godina nakon postavljanja primarne dijagnoze. Zaključak: Lokalno uznapredovali i metastatski oblik BCC su i dalje retki oblici ovog karcinoma kože. Ovaj izveštaj slučaja može pomoći lekarima kliničarima u pravovremenom postavljanju dijagnoze i adekvatnom planiranju lečenja. 

 

Ključne riječi

lokalno uznapredovali bazocelularni karcinom, metastatski bazocelularni karcinom, etiopatogeneza, „hedgehog“inhibitori

 

 

 

Abstract

 

Introduction: Basal cell carcinoma (BCC) of the skin is the most common type of skin cancer with a constant increase in the global incidence of the disease. It represents about 80% of all non-melanoma skin cancers, and originates from basal cells of the epidermis. It is characterized by locally destructive growth, which can have consequences on functional and aesthetic outcomes and with rare occurrence of metastases. Currently available methods of BCC treatment are surgical and non-surgical. Case report: We report on our experience with a patient who underwent primary excision of BCC skin of the naso-orbital region at age 45 and who then developed locally advanced BCC and the metastatic BCC, with an evolution of 9 years after primary diagnosis. Conclusion: Locally advanced and metastatic forms of BCC are still rare forms of this skin cancer.This case report can help clinicians make timely diagnoses and plan treatment appropriately.

Key words:

laBCC, mBCC, etiopathogenesis, “hedgehog” inhibitors

 

 

 

 

References:

1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069-80.
2. Piva de Freitas P, Senna CG, Tabai M, Chone CT, Altemani A. Metastatic basal cell carcinoma: A rare manifestation of common disease. Case Rep Med. 2017;2017:8929745
3. Verkouteren JAC, Ramadas KHR, Wakkee M, Nijsten T. Epidemiology of basal cell carcinoma: scholarly review. Br J Dermatol. 2017;177(2):359-72.
4. Asgari MM, Moffet HH, Ray GT, Quesenberry CP. Trends in basal cell carcinoma incidence and identification oh high-risk subgroups, 1998-2012. JAMA Dermatol. 2015;151(9):976-81.
5. Bonilla X, Paramentier L, King B, Bezrukov F, Kaya G, Zoete V, et al. Genomic anlysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Gent. 2016;48(4):398-406.
6. Trakatelli M, Morton C, Nagore E, Ulrich C, Del Marmol V, Peris K, et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol. 2014;24(3):312-29.
7. McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014;50(4):774-83.
8. Lau J, Guminski AD, Gill AJ, Veivers D. Metastatic basal cell carcinoma: A review of six cases. Aust J Otolaryngol. 2018;1:20.
9. Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004;23(3-4):389-402.
10. Koelblinger P, Lang R. New developments in the treatment of basal cell carcinoma: Update on current and emerging treatment options with a focus on vismodegib. Onco Targets Ther. 2018;11:8327-340.
11. Schmults CD, Daniel GA, Nghiem, Puzanov I. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Basal Cell Carcinoma. 2019;44. NCCN, Pennsylvania, USA.
12. Sekulic A, Midgen MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-9.
13. Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dreno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16(6):729-36.
14. Fram BR, Strony J, Jagannathan G, Brown SA. Cutaneous basal cell carcinoma with bone metastasis. An OrthopaedicCase Report. Case Rep Orthop. 2019;2019:1628980.
15. Rodriguez C, Barriuso V, Chan LS. Extensive basal cell carcinoma with probable bone metastasis. Cutis. 2007;80(1):60-6.
16. Millan-Cayetano JF, Blazquez-Sanchez N, Fernandez-Canedo I, Repisio-Jimenez JB, Funez-Liebana R, Bautista MD, et al. Metastatic basal cell carcinoma: Case report and review of the literature. Indian J Dermatol. 2020;65(1):61-4.
17. Totonchy M, Leffell D. Emerging concepts and recent advances in basal cell carcinoma. F1000Res. 2017;6:2085.
18. Fecher LA, Sharfman WH. Advanced basal cell carcinoma, the hedgehog pathway, and treatment options-role of smoothened inhibitors. Biologics. 2015;9:129-40.
19. McDaniel B, Badri T, Steele RB. Basal cell carcinoma. [Updated 2021 Sep 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov.books/NBK482439?report=classic
20. Mackiewicz-Wysocka M, Bowszyc-Dmochowska M, Strzelecka-Weklar D, Danczak-Pazdrowska A, Adamski Z. Basal cell carcinoma - diagnosis. Contemp Oncol (Pozn). 2013;17(4):337-42.
21. Stanoszek LM, Wang GY, Harms PW. Histologic mimics of the basal cell carcinoma. Arch Pathol Lab Med. 2017;141(11):1490-502.
22. Peris K, Fargnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based Interdisciplinary guidelines. Eur J Cancer. 2019;118:10-34.
    

PDF: 10-MD-Vol 13 No 3-4 Sept-Dec 2021_Tešić M. et al.pdf